JP
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Whitepaper
Genetically engineered PDX models as patient avatars in preclinical evaluation of acute leukemias
Dr. Irmela Jeremias from Helmholtz Munich and her team are using gene silencing techniques to evaluate the relevance of specific tumor alterations in PDX models. The aim is to discover dependencies and drug targets in acute leukemias to improve patients’ treatment and prognosis outcomes. And they’ve done just that — read the whitepaper to learn more about the study.
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
Genetically engineered PDX models as patient avatars in preclinical evaluation of acute leukemias